Abstract: A high tenacity regenerated cellulosic fiber is disclosed. Said high tenacity regenerated cellulosic fiber is prepared from a cellulosic raw material, wherein the cellulosic raw material comprises 5-100 wt % of a pre-treated bacterial cellulose having a degree of polymerization in a range of 450-2000; and 0 to 95 wt % of an additional cellulosic material selected from a group consisting of dissolving grade pulp, recycled cotton pulp, reclaimed cellulosic material and a mixture thereof. Said fiber has a tenacity of at least 4.5 grams/denier and elongation of at least 10%, measured in accordance with ASTM D 3822.

Abstract: The present invention relates to an apparatus for the mass production of polymeric nanofibres and their uniform deposition over any substrate. The present invention also provides a method for the manufacture of droplet free polymeric nanofibres by electrospinning process using multi-hole spinnerets. The droplet free polymeric nanofibres of the present invention are preferably of a diameter in the range of 50 nm to 850 nm.

Abstract: The present invention relates to an apparatus for the mass production of polymeric nanofibres and their uniform deposition over any substrate. The present invention also provides a method for the manufacture of droplet free polymeric nanofibres by electrospinning process using multi-hole spinnerets. The droplet free polymeric nanofibres of the present invention are preferably of a diameter in the range of 50 nm to 850 nm.

Abstract: The present invention in general relates Hemoglobin receptor or its part as a novel vaccine candidate against Leishmaniasis. Specifically, the present invention envisages HbR DNA for eliciting immune response in a mammal against Leishmaniasis. Additional aspect of the present invention is related to a vaccine composition for inducing immune response against Leishmaniasis in mammals. In a preferred aspect, the present invention relates to use of HbR-polypeptide as marker for diagnosis of Leishmania in kala-azar patients.

Abstract: The present invention in general relates Hemoglobin receptor or its part as a novel vaccine candidate against Leishmaniasis. Specifically, the present invention envisages HbR DNA for eliciting immune response in a mammal against Leishmaniasis. Additional aspect of the present invention is related to a vaccine composition for inducing immune response against Leishmaniasis in mammals. In a preferred aspect, the present invention relates to use of HbR-polypeptide as marker for diagnosis of Leishmania in kala-azar patients.

Abstract: In a computer network, services are provisioned for a user over the network, typically via a series of messages. Depending on the particular service to be provisioned many network entities may be concerned with the provision of a particular service. However, an initiator of a service request may be unaware of all the network entities concerned with a service provision request. A system which receives a single request for service provisioning from an initiator, determines each network entity corresponding to the request from a common repository of network entities, and applies the operations concerned with the service provision request at each corresponding network entity, allows a service to be provisioned without manually searching and examining the network to determine the network entities concerned with a particular service provision request.